Teva- Pharmaceutical Industries Ltd. TEVA

NYS: TEVA | ISIN: US8816242098   25/03/2026
29,46 USD (+1,10%)
(+1,10%)   25/03/2026

19 maart 2026 · Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 · Persbericht

19 maart 2026 · Teva Releases Q1 2026 Aide Memoire · Persbericht

3 maart 2026 · Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug · Persbericht

24 februari 2026 · Teva to Present at the Upcoming Investor Conferences in March · Persbericht

20 februari 2026 · U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults · Persbericht

17 februari 2026 · Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease · Persbericht

28 januari 2026 · Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential · Persbericht

27 januari 2026 · Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’ · Persbericht

14 januari 2026 · AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine · Persbericht

12 januari 2026 · Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation · Persbericht

11 januari 2026 · Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo · Persbericht

5 januari 2026 · Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference · Persbericht

24 december 2025 · S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive · Persbericht

19 december 2025 · Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® · Persbericht

12 december 2025 · Teva Releases Q4 2025 Aide Memoire · Persbericht

12 december 2025 · Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 · Persbericht

9 december 2025 · Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults · Persbericht

26 november 2025 · Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva® · Persbericht

25 november 2025 · Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® · Persbericht

21 november 2025 · Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December · Persbericht

Mijn selecties